Patent ID: 8617545
Filing Date: 2013-12-31
Classification: C12Q,G01N

Abstract:
1. A method for monitoring efficacy of an antagonist to BAFF (SEQ ID NO:30) in a human, comprising the steps of administering the BAFF antagonist to the human, obtaining from the human a biological sample comprising B cells, and detecting a level in the biological sample of one or more molecules selected from the group consisting of: (a) a polypeptide comprising a sequence selected from SEQ ID NO:16, SEQ ID NO:17, and SEQ ID NO:18; and (b) an mRNA comprising a nucleotide sequence encoding an amino acid sequence selected from SEQ ID NO:16, SEQ ID NO:17, and SEQ ID NO:18, wherein the level, relative to a control, of at least one of the detected molecules indicates efficacy of the BAFF antagonist in the human, and wherein the BAFF antagonist inhibits the interaction between BAFF and a BAFF receptor and is selected from the group consisting of an anti-BAFF antibody, an anti-BAFF-R antibody, and a BAFF-R-Fc polypeptide.